The Mitochondrial Diseases drugs in development market research report provides comprehensive information on the therapeutics under development for Mitochondrial Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mitochondrial Diseases. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mitochondrial Diseases and features dormant and discontinued products.

GlobalData tracks 33 drugs in development for Mitochondrial Diseases by 26 companies/universities/institutes. The top development phase for Mitochondrial Diseases is discovery with 15 drugs in that stage. The Mitochondrial Diseases pipeline has 31 drugs in development by companies and two by universities/ institutes. Some of the companies in the Mitochondrial Diseases pipeline products market are: Primera Therapeutics, Abliva and PTC Therapeutics.

The key targets in the Mitochondrial Diseases pipeline products market include Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31), Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha (Ligand Effect Modulator 6 or PPARGC1A), and NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 2.3.1.286).

The key mechanisms of action in the Mitochondrial Diseases pipeline product include Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31) Activator with three drugs in Preclinical. The Mitochondrial Diseases pipeline products include two routes of administration with the top ROA being Oral and six key molecule types in the Mitochondrial Diseases pipeline products market including Small Molecule, and Gene Therapy.

Mitochondrial Diseases overview

Mitochondrial diseases are a group of genetic conditions that affect how mitochondria function in your body. Mitochondria are the organelles that produce energy for the cell and are found in every cell of the human body except red blood cells. They convert the energy of food molecules into the ATP that powers most cell functions. Mitochondrial diseases can affect almost any part of your body, including the brain, nerves, muscles, kidneys, heart, liver, eyes, ears and pancreas. Mitochondrial diseases can emerge at any age and are enormously diverse in their clinical and molecular features. Some of the most common types of mitochondrial diseases are MELAS syndrome, LHON, Leigh syndrome, KSS, and MERRF. Mitochondrial diseases are diagnosed by a combination of clinical symptoms, biochemical tests, genetic tests and muscle biopsies. There are no cures for mitochondrial diseases, but treatment can help manage the symptoms and prevent complications.

For a complete picture of Mitochondrial Diseases’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.